RXEI Stock Overview
RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
RxElite, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -99.50% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| RXEI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.08% | 1.2% |
| 1Y | n/a | 13.2% | 24.9% |
Return vs Industry: Insufficient data to determine how RXEI performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RXEI performed against the US Market.
Price Volatility
| RXEI volatility | |
|---|---|
| RXEI Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RXEI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RXEI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.piramalcriticalcare.com |
RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its products include Sterile Liquid Dose products that consist of generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, and injectable drugs. The company, through its subsidiaries, also manufactures active pharmaceutical ingredients for pharmaceutical companies in the United States, Europe, and Asia.
RxElite, Inc. Fundamentals Summary
| RXEI fundamental statistics | |
|---|---|
| Market cap | US$116.00 |
| Earnings (TTM) | -US$29.23m |
| Revenue (TTM) | US$10.44m |
0.0x
P/S Ratio0.0x
P/E RatioIs RXEI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXEI income statement (TTM) | |
|---|---|
| Revenue | US$10.44m |
| Cost of Revenue | US$9.24m |
| Gross Profit | US$1.20m |
| Other Expenses | US$30.43m |
| Earnings | -US$29.23m |
Last Reported Earnings
Sep 30, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did RXEI perform over the long term?
See historical performance and comparison